SQ31f is a potent non-tuberculous mycobacteria antibiotic by specifically targeting the mycobacterial F-ATP synthase
SQ31f represents an attractive inhibitor to tackle the issues associated with NTM drug tolerance and toxicity. Its combinatory potency with anti-M. abscessus drugs holds potential for overcoming resistance, while also reducing intensive compound synthesis and associated costs.
Authors
- Wassim Daher (ORCID: https://orcid.org/0000-0001-9026-5333)
- Gerhard Grüber (ORCID: https://orcid.org/0000-0002-5730-8319)
- Priya Ragunathan (ORCID: https://orcid.org/0000-0002-2039-4890)
- Patcharaporn Sae‐Lao
- Françoise Roquet‐Banères (ORCID: https://orcid.org/0000-0003-2636-3734)
- Laurent Kremer (ORCID: https://orcid.org/0000-0002-6604-4458)
- Amaravadhi Harikishore (ORCID: https://orcid.org/0000-0001-6552-1534)
- Roderick W. Bates (ORCID: https://orcid.org/0000-0002-8115-4970)
Institutions
- Agency for Science, Technology and Research (SG)
- Inserm (FR)
- Nanyang Technological University (SG)
- Université de Montpellier (FR)
- Centre National pour la Recherche Scientifique et Technique (CNRST) (MA)
- Institut de Recherche en Infectiologie de Montpellier (FR)
- Bioinformatics Institute (SG)
Publication Details
- Journal
- Journal of Antimicrobial Chemotherapy
- Published
- 2024-11-05
- DOI
- https://doi.org/10.1093/jac/dkae406
- Citations
- 6
- Primary Topic
- Tuberculosis Research and Epidemiology
- Type
- article
- Field-Weighted Citation Impact
- 2.33
Funders
- National Research Foundation
- Fondation pour la Recherche Médicale